Additional European Equity News

Newsquawk ·

Burberry (BRBY LN) - Q4 2026 (GBP): Revenue 2.42bln (prev. 2.46bln Y/Y), Adj. Op. Profit 160mln (prev. 26mln Y/Y). Retail comp sales +5% (exp. +4.6%). CEO : “We’ve returned to profitable comparable sales growth, with a strong fourth quarter driven by momentum in Greater China and Americas. Our strategy is working and there are clear opportunities for further growth”. By Region: Returned to comparable sales growth from Q2, with sequential improvement throughout the year; particular strength in Greater China and Americas, both up double digit in Q4. FY27 Outlook: “In FY27 we expect to make further progress on our financial ambitions, including delivering revenue growth and margin expansion”. Wholesale is expected to grow by mid-single digit percentage in H1 FY27. Board Update: Chair Gerry Murphy has decided to retire, effective November 2026. (Burberry) Ipsen (IPN FP) - Co. unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI, at the SCALE Symposium. Phase II data in glab

AI 시장 분석

Burberry (BRBY LN) reported Q4 revenue of 2.42bln (previous 2.46bln Y/Y) and adjusted operating profit of 160mln (previous 26mln Y/Y), with retail like-for-like sales up 5%, slightly above the 4.6% expectation. Demand recovery was particularly pronounced in Greater China and the Americas, where quarterly double-digit growth led management to target revenue growth and margin expansion for FY27. Wholesale is expected to see mid-single-digit unit growth in H1 FY27, indicating a mixed channel recovery. Separately, chairman Gerry Murphy's announced retirement in November 2026 may act as a governance variable. Ipsen (IPN FP) unveiled the first-in-class recombinant neuroinhibitor corabotase at the SCALE symposium, suggesting Phase II data and drawing interest in biotech, aesthetic, and neurological treatment areas.

상승 영향

하락 영향

AI가 생성한 분석으로 투자 자문이 아닙니다.

DYAX Investor Sentiment

Bullish (Long) 65% · Bearish (Short) 35%

407 participants

Related News

원문 보기 — Newsquawk